First phase II/III trial to verify the efficacy and safety of trifluridine/tipiracil plus bevacizumab as second-line treatment for patients with metastatic colorectal cancer
Contributors: Yasutoshi Kuboki and Takayuki Yoshino;
Department of Experimental Therapeutics and Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
Recent Comments
A blog for our paper recently published in British Journal of Cancer: Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial